

24 June 2015

OBJ FILES PATENT ON NEW TECHNOLOGY PLATFORM

OBJ Limited (ASX: OBJ) ("**OBJ**") is pleased to announce the filing of an international patent and the launch of its newest breakthrough in enhanced skin penetration technology.

Dynamically Configurable Emulsion technology ("**DCE**") is the result of 18 month's development work and has resulted in the world's first technology for the management and control of emulsions during application to the skin.

DCE was developed by OBJ's Perth-based skin science team to manipulate the structure and performance of emulsion-based products during application to the skin.

Emulsions are the most common type of formulation used by pharmaceutical, skin care and cosmetic companies. Emulsions are favoured by these industries due to their low manufacturing cost, long shelf life and even distribution of active ingredients. Once made, the internal stability of emulsions can often limit the functionality of the emulsion and the bioavailability of key active ingredients.

DCE technology uses a number of physical energy forms to interact directly with intermolecular bonds that give emulsions stability and a second set of surface energies to orderly layer the components into benefited configurations during application to the skin by the consumer.

DCE's unique ability to take a standard low-cost emulsion and transform it into a self-occluding, self-assembling, multi-layer product during consumer usage is expected to have wide industry appeal.


"DCE is very much a market driven technology", explained Jeff Edwards, head of the Company's technical developments. "The advent of DCE provides OBJ with a much broader technology platform to allow the Company to participate in certain market sectors where the Company is limited in its ability to meet wider global demands for enhanced skin penetration. DCE provides us with an additional platform for wider commercial activity whilst allowing the Company to offer additional platform technologies to our existing partners."

The new DCE technology is an example of the way the Company has advanced its relationship with its international partners in recent times. Where OBJ was once seen as specialising in magnetic microarrays, OBJ is now consulted by its partners in all aspects of product performance, enhanced and innovative device design and manufacture. OBJ worked closely with its partners to take the SK-II Eye Wand from initial concept to launch in less than 9 months establishing a new innovation pathway that is now being explored by multiple parties.

While DCE may represent a substantial breakthrough in formulation management, it has its roots firmly grounded in OBJ's increasing expertise in physical rather than chemical enhancement technologies and products.

OBJ Limited

leaders in magnetic micro-array drug delivery



About OBJ:

OBJ develops proprietary magnetic micro-array drug delivery and product enhancement technologies for the pharmaceutical, healthcare and consumer goods sectors.

OBJ partners companies in the design and development of next generation products using physical science rather than chemistry to provide new levels of product performance without the cost of reformulation or new ingredient approvals.

OBJ offers a portfolio of proprietary technologies and supports partners by providing IP-protected market exclusivity, expertise in magnetic array design, feasibility and efficacy and claims testing, engineering and production.

About OBJ's Technologies:

OBJ has developed a platform of physical enhancement technologies based on low-cost magnetic micro-arrays that influence the movement and penetration of drugs, active ingredients and formulations at the molecular level.

Complex 3-D array and moving magnetic fields have the ability to repulse certain molecules to enhance diffusion and to alter the permeability of certain biological and non-biological targets.

OBJ develops low cost micro-array film technology that utilises diamagnetic repulsion, induced permeation and energy redirection to offer a new way of managing the speed, depth of penetration and delivery of active ingredients in a wide range of pharmaceutical and consumer products.

Forward-looking Statements

This announcement contains certain "forward-looking statements" concerning OBJ. Where OBJ expresses or implies an expectation or belief as to future events or results, such expectation or belief is expressed in good faith and believed to have a reasonable basis.

Forward-looking statements provided in this announcement are based on assumptions and contingencies which are subject to change without notice. Such forward-looking statements including statements regarding intentions, planned events and potential results are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance.

There can be no assurance that actual outcomes will not differ materially from these forward-looking statements, and there are risks associated with OBJ and the industry which may affect the accuracy of the forward-looking statements. OBJ does not undertake any obligation to release publicly any revisions to any forward looking statement to reflect events or circumstances after the date of this announcement or to reflect the occurrence of unanticipated events, except as may be required under applicable securities laws.

For more information:

OBJ Ltd:

Mr Glyn Denison
Director

Telephone +618 9443 3011
Email info@obj.com.au
Web www.obj.com.au

ABN 72 056 482 636

284 Oxford Street, Leederville 6007 Perth, Western Australia

Telephone +61 8 9443 3011 Facsimile +61 8 9443 9960

www.obj.com.au